In vivo, c-Src inhibition improved diabetes-induced glomerular hypertrophy, partial glomerulosclerosis, mesangial cells hyperplasia and hypertrophy, inflammatory cell infiltration, mesangial expansion, collagen deposition, tubular ectasia and cell swelling, and interstitial fibrous tissue proliferation in the diabetic kidneys. The gene discussed is SRC; the disease is diabetes mellitus.